Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...

CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates Entered into ...

The deal helps move BioNTech’s proposed acquisition of CureVac closer to completion. With the settlement, GSK said it will tender the CureVac shares it owns in support of the $1.25 billion acquisition ...

GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...

CureVac (NASDAQ:CVAC) announced on Friday that the company and its partner, GSK (NYSE:GSK), are set to receive $740M and other payments, as Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) have agreed to ...

Drug developers GlaxoSmithKline plc and CureVac NV have announced plans to work jointly on vaccines against emerging Covid-19 variants of the coronavirus. In addition, GSK will help manufacture up ...

CureVac, the German biotech that focuses on mRNA vaccines, will receive an initial payment of €400 million upfront ($430 million) from GSK, and is eligible for another €1.05 billion ($1.1 ...

GSK and CureVac teamed up in February in a 150 million euro ($177 million) deal to develop the next-generation COVID-19 vaccine from next year, in an attempt to tackle several variants with one shot.

The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

GSK and CureVac teamed up in February in a 150 million euro ($177 million) deal to develop the next-generation COVID-19 vaccine from next year, in an attempt to tackle several variants with one shot.